{"id":"NCT04681729","sponsor":"Sanofi","briefTitle":"Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-10","primaryCompletion":"2023-02-02","completion":"2023-04-20","firstPosted":"2020-12-23","resultsPosted":"2024-02-21","lastUpdate":"2025-09-10"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cold Urticaria"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Non sedating H1-antihistamine","otherNames":[]}],"arms":[{"label":"Dupilumab","type":"EXPERIMENTAL"},{"label":"Matched Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine\n\nSecondary Objectives:\n\nTo demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU disease control To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU local signs and symptoms (hives/wheals, itch, burning sensation and pain) after provocation test To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU disease activity To demonstrate improvement in health-related quality-of-life and overall disease status and severity To evaluate the ability of dupilumab in reducing the proportion of participants who require rescue therapy To evaluate the proportion of participants with cold exposure triggered urticaria To evaluate safety outcome measures To evaluate immunogenicity of dupilumab","primaryOutcome":{"measure":"Percentage of Participants With Negative Ice Cube Provocation Test at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":37.5,"sd":null},{"arm":"Dupilumab","deltaMin":40.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9492"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":33,"countries":["United States","Argentina","Canada","Germany","Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25251&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Covid-19","Injection Site Reaction","Injection Site Pain","Suspected Covid-19","Injection Site Erythema"]}}